← All trials
NCT06366087
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2024
- Primary completion
- May 15, 2024
- Completion date
- May 22, 2024
- First posted
- Apr 15, 2024
- Last posted
- Jul 18, 2024
- Enrollment
- 46
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Department of Health and Human ServicesLead sponsor
- AllucentCollaborator
- Rho, Inc.Collaborator
- Department of Health and Human ServicesOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.